New hope for tough lung cancer: onvansertib trial targets relapsed small cell

NCT ID NCT05450965

Recruiting now Disease control Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing a drug called onvansertib in about 37 people with small cell lung cancer that has come back or hasn't responded to chemotherapy. Onvansertib works by blocking a protein that cancer cells need to grow and repair themselves. The main goal is to see if the drug can shrink tumors, while also checking for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Onvansertib (a drug that blocks a protein called PLK1, which helps cancer cells grow and repair themselves)
What this could lead to: If successful, this could provide a new treatment option for people with small cell lung cancer whose disease has returned or who cannot tolerate standard chemotherapy.
What could go wrong: This is an early phase 2 trial with only 37 participants, so results may not apply to everyone. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung neoplasm small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL CELL LUNG CANCER SMALL CELL LUNG CARCINOMA

Contacts and locations

Locations

UPMC Hillman Cancer Center
ACTIVE_NOT_RECRUITING

Pittsburgh, Pennsylvania, 15232, United States
University of Maryland Greenebaum Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.